Antonio Monzón Moreno, M. Cameán Fernández, Vicente Merino Bohórquez, Gabriel Ramírez Soto
The monoclonal antibody bevacizumab has been widely used using intravitreal syringes to treat age-related macular degeneration, even though it has not been officially approved for this indication (off-label use). On the other hand, ranibizumab has been officially approved for this indication. Bevacizumab could have other off-label uses (retinal vein occlusion, diabetic retinopathy, neovascular glaucoma, diabetic macular edema, etc). The objective of this paper is to review the off-label uses of bevacizumab and to present a proposal of the procedure for preparing intravitreal syringes of bevacizumab. Conclusions: some bibliographic documentation exists to support some of the off-label uses of bevacizumab, and we present a proposal of a procedure for preparing intravitreal syringes of bevacizumab with the best quality guarantees
© 2001-2024 Fundación Dialnet · Todos los derechos reservados